News

Pyoderma Gangrenosum Market Set For Expansion With Orphan Drug Designations And Pipeline Acceleration Delveinsight
In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...
24/7 Wall St. on MSN7d
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good ...
24/7 Wall St. on MSN9d
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential
After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...